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http://dx.doi.org/10.1016/j.jaci.2016.08.008patients with 1 or more event was also assessed. All
mepolizumab doses were combined and individual patient-level
data were analyzed.
Results: Four studies (n 5 1388) were eligible for inclusion.
Mepolizumab significantly reduced the rate of exacerbations
requiring hospitalization (relative rate, 0.49; 95% CI, 0.30-0.80;
P 5 .004) and hospitalization/emergency room visit (relative
rate, 0.49; 95% CI, 0.33-0.73; P < .001) versus placebo.
Significant reductions of 45% and 38% were also observed for
the proportion of patients experiencing 1 or more
hospitalization and hospitalization and/or emergency room visit,
respectively.
Conclusions: Mepolizumab approximately halved exacerbations
requiring hospitalization and/or emergency room visits
compared with placebo in patients with severe eosinophilic
asthma. This treatment addresses a key outcome in a patient
population with a high unmet need (GSK Study 204664). (J
Allergy Clin Immunol 2016;nnn:nnn-nnn.)
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Severe asthma is a heterogeneous disease comprising several
diverse phenotypic subgroups.1,2 One subgroup is characterized
by increased blood and sputum eosinophil counts.3,4 Typically,
these patients have frequent exacerbations and suboptimal asthma
control despite intensive use of guideline-directed asthma thera-
pies, including the use of maintenance systemic corticosteroids
in many patients.1 Asthma exacerbations are often of sufficient
severity to require hospitalization or a visit to the emergency
room,5,6 accounting for a large proportion of asthma-related
morbidity, mortality, and health care costs.7-11 The prevention
of severe asthma exacerbations is therefore amajor goal of asthma
management.8
Mepolizumab is a humanized mAb against IL-5, which
primarily inhibits eosinophilic inflammation,12,13 and has been
shown to decrease sputum and blood eosinophil levels in patients
with severe eosinophilic asthma.3,14,15 To date, all the random-
ized, placebo-controlled studies of mepolizumab in this patient
population have reported a reduction compared with placebo in
the frequency of clinically significant exacerbations, defined as
worsening of asthma that required use of/increased use of
systemic corticosteroids.3,15-18 Although this definition includes
exacerbations that require hospitalization and/or a visit to the
emergency room, the sample sizes of individual studies were
insufficient for assessing these relatively infrequent events. The
aim of this meta-analysis was therefore to assess the rate of
exacerbations requiring hospitalization or an emergency room
visit in clinical studies of mepolizumab compared with placebo
in patients with severe eosinophilic asthma.1
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This meta-analysis was conducted according to Preferred Reporting Items
for Systematic reviews and Meta-Analyses (PRISMA) statement,19 including
search strategy, selection criteria, data extraction, and data analysis based on a
defined review protocol (GSK etrack no. 20466420).Identification of eligible studies
Studies eligible for inclusion were any randomized study comparing
mepolizumab with placebo in patients with severe eosinophilic asthma of at
least 24 weeks duration that involved at least 6 doses of the study drug.
Studies were identified using a search strategy on PubMed of (‘‘clinical
trial’’[Publication Type]) AND (mepolizumab[Title]) AND (asthma[Title])
and a search of completed studies on the GSK clinical trial register of
‘‘mepolizumab’’ and ‘‘asthma.’’ Clinicaltrials.gov was also searched to find
any completed, unpublished studies that met the inclusion criteria. These
searches were carried out in May 2015.Data extraction and outcome measures
Individual patient-level data were obtained from the GSK clinical trial
databases and from the relevant investigating centers. Data used in these
studies included study design, patient population, follow-up period for
exacerbations, study drug and dose, number of hospitalizations, and number
of emergency room visits. The intent-to-treat population was analyzed, and
comprised all randomized patients who received 1 or more dose of study
medication. Asthma exacerbations reported from the start of treatment until
completion of the study or up towithdrawal (but less than 4weeks after the last
dose of study medication) were included in the analysis. Asthma
exacerbations separated by less than 7 days were considered a continuation
of the same exacerbation.21 Hospitalization included intensive care unit
admission and intubation.
The primary end points of this meta-analysis were (1) annual rate of
exacerbations requiring hospitalization and (2) annual rate of exacerbations
requiring a hospitalization and/or an emergency room visit. The proportion of
patients with 1 or more exacerbation requiring hospitalization, the proportion
of patients with 1 or more exacerbation requiring hospitalization/emergency
room visit, and time to first exacerbation requiring hospitalization and
hospitalization and/or emergency room visit were also assessed. Because
previous studies have shown similar reductions in exacerbations based on a
10-fold dose range of mepolizumab or by a route of administration
(intravenous [IV] vs subcutaneous [SC]),3,17 all mepolizumab doses
were combined for analysis and compared with placebo. In addition,
a prespecified sensitivity analysis was carried out using only comparable doses
of mepolizumab (75 mg IV and 100 mg SC).Statistical analysis
The meta-analysis was conducted using SAS version 9.3 (SAS Institute,
Cary, NC). The number of exacerbations requiring hospitalization/emergency
room visit and the number of exacerbations requiring hospitalization were
assumed to follow a negative binomial distribution.22Meta-analysis of relative
rates of exacerbations was performed using the inverse variance fixed effects
method to combine estimated rate ratios and standard errors from each
individual study. Meta-analysis of relative risks for the proportion of patients
with at least 1 exacerbation was performed using Mantel-Haenszel
methods. Kaplan-Meier curves of time to first exacerbation were constructed
using a weighted average of the curves for the individual studies, with
Mantel-Haenszel weights for each study.23 All outcomes were reported with95% CIs. Statistical heterogeneity was tested with the I2 statistic, with
I2 <_ 50% indicating no significant heterogeneity.24RESULTS
Description of studies
A summary of the mepolizumab studies identified through
the search strategy is provided in Fig 1 and in Table E1 in this
article’s Online Repository at www.jacionline.org. A total of 12
potentially eligible articles were identified after removal of
duplicates.3,15-18,25-31 Four studies were identified as meeting
the inclusion criteria: DREAM (NCT01000506),3 MENSA
(NCT01691521),17 SIRIUS (NCT01691508),16 and the 2009
study by Haldar et al15 (ISRCTN75169762). The study by Nair
et al18 was excluded because the treatment period was less than
24 weeks and included 5 administrations of the study drug
rather than the 6 required to meet the prespecified inclusion
criteria. Furthermore, there were no exacerbations requiring
hospitalization or an emergency room visit reported in this study,
and, therefore, inclusion of this study would not affect the results.
SIRIUS could not be included in the analysis of rates of
exacerbation requiring hospitalization because there were no
exacerbations requiring hospitalization in the mepolizumab arm
of the study, therefore no variability could be associated with
the rate reduction for this study. Similarly, Haldar et al’s 2009
study could not be included in the analysis of hospitalization/
emergency room visit rates because data were not available for
emergency room visits. The sensitivity analysis excluded the
SIRIUS study because it was primarily an oral-sparing study
and excludedHaldar et al’s 2009 study because the study included
only the 750 mg IV dose.
Most of the inclusion criteria for DREAM, MENSA, SIRIUS,
and Haldar et al’s 2009 study were similar (Table E1), with the
following differences of note: Haldar et al15 included only adults
(18 years or older), whereas DREAM, MENSA, and SIRIUS
included patients 12 years or older; DREAM, MENSA, and
Haldar et al15 included only those patients who had 2 or more
exacerbations requiring corticosteroid treatment in the previous
year, whereas SIRIUS required the use of maintenance oral
corticosteroids (OCSs); definition of eosinophilic asthma in
DREAM was not confined to peripheral blood eosinophil levels;
Haldar et al15 used sputum eosinophils to define eosinophilic
asthma. Patients in all 4 studies met the American Thoracic
Society definition of severe asthma,4 requiring treatment with
high-dose inhaled corticosteroids plus a second controller therapy
to prevent it from becoming uncontrolled or which remains
uncontrolled despite this therapy.
Across all studies, 1388 patients received either mepolizumab
intravenously (75 mg, 250 mg, or 750 mg), mepolizumab
subcutaneously (100 mg), or placebo approximately every
4 weeks in addition to their baseline standard of care (which
included high-dose inhaled corticosteroids and additional asthma
control medications). Baseline demographic characteristics of the
patients in these studies are described in Table I. The mean age of
the patients in each study was approximately 50 years, with a
mean asthma duration of 17 to 24 years. Baseline blood
eosinophil counts were similar across all studies (with geometric
means ranging from 230 to 350 cells/mL), and the mean
number of severe exacerbations in the previous year ranged
between 2.9 and 5.5. Overall, 36% of patients were on
maintenance OCS at the start of the studies. Lung function,
Records identified from
PubMed
(N=9)
Records identified from 
GSK clinical trial register
(N=6)
Records after duplicates 
removed
(N=12)
Full-text articles 
assessed for eligibility
(N=5)
Studies included in 
meta-analysis
(N=4)
Records excluded (N=1)
1 study <24 weeks
Records excluded (N=7)
2 studies no placebo arm
2 secondary manuscripts
1 genetic sub study
1 review article
1 moderate asthma
Identification
Screening
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FIG 1. Flow of study identification, inclusion, and exclusion. Studies excluded: GSK Study 114092
(NCT01366521),25 GSK Study 115661 (NCT01842607),26 Prazma et al,27 Haldar et al,28 GSK study 201318
(genetic substudy),29 Antoniu,30 Flood-Page et al,31 and Nair et al.18
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lator and postbronchodilator FEV1, varied across studies from
58% to 75% and 68% to 78%, respectively.Risk of bias in individual studies
All 4 studies were considered to have a low risk of bias.
The study publications described appropriate methods for
randomization, including sequence generation, allocation
concealment, and blinding. In addition, the databases contained
appropriate outcome data for exacerbations requiring hospitali-
zation and/or an emergency room visit. There was no risk of
publication bias because all studies with mepolizumab were
known to the authors. In addition, clinicaltrials.gov did not reveal
any completed, unpublished studies that met the inclusion
criteria.Exacerbations
When combining the results from the studies, 5.6% versus
9.5% of patients receiving mepolizumab (all doses, pooled) or
placebo, respectively, experienced 1 or more exacerbation
requiring hospitalization, increasing to 9.5% versus 14.1% for
combined hospitalization/emergency room visits (Table II).
Compared with placebo, there was a significant reduction of
45% in the proportion of patients experiencing an exacerbation
requiring hospitalization (relative risk, 0.55; 95% CI, 0.36-0.83;
P 5 .004) and a significant reduction of 38% in the proportion
of patients experiencing an exacerbation requiring hospitaliza-
tion/emergency room visits with mepolizumab (relative risk,
0.62; 95% CI, 0.45-0.86; P 5 .004) (Fig 2, A). Similar resultswere obtained in the sensitivity analysis for patients on the pooled
75 mg IV/100 mg SC doses of mepolizumab with a reduction of
38% (P 5 .066) for hospitalization and 43% (P 5 .004) for
hospitalization/emergency room visits compared with placebo
(Fig 2, B). Some patients experienced more than 1 exacerbation
requiring hospitalization and/or an emergency room visit. For
example, in DREAM, 11 of 155 (7%) patients on placebo had
more than 1 exacerbation requiring hospitalization/emergency
room visit and 6 of 155 (4%) had more than 1 exacerbation
requiring hospitalization.
Kaplan-Meier curves of time to first exacerbation requiring
hospitalization and of time to first exacerbation requiring
hospitalization or an emergency room visit are provided in Fig 3.
Analysis of rate of exacerbations shows that exacerbations
requiring hospitalization were significantly reduced by 51%
(relative rate, 0.49; 95% CI, 0.30-0.80; P 5 .004) for patients
on mepolizumab (all doses, pooled), compared with placebo
(Fig 4). Similarly, exacerbations requiring hospitalization
and/or an emergency room visit were significantly reduced
by 51% (relative rate, 0.49; 95% CI, 0.33-0.73; P < .001).
This effect was also observed in the sensitivity analysis for
the mepolizumab 75 mg IV/100 mg SC pooled doses, with a
significant reduction of 48% (P 5 .027) in hospitalization rates
and 54% (P 5 .001) in hospitalization/emergency room visit
rates, compared with placebo (Fig E1). In all analyses, the
results were consistent between individual studies, with no
heterogeneity shown for each outcome across the studies
(I2 5 0%). Absolute rates per year of exacerbations requiring
hospitalization and hospitalization and/or an emergency room
visit after treatment with mepolizumab or placebo are also
presented in Table III.
TABLE I. Patients’ characteristics from studies of mepolizumab of at least 24-wk duration
Characteristic
DREAM3 (N 5 616) MENSA17 (N 5 576) SIRIUS16 (N 5 135) Haldar et al15 (N 5 61)
Mepo
Placebo
(n 5 155)
Mepo
Placebo
(n 5 191)
Mepo
Placebo
(n 5 66)
Mepo
Placebo
(n 5 32)
75 IV
(n 5 153)
250 IV
(n 5 152)
750 IV
(n 5 156)
75 IV
(n 5 191)
100 SC
(n 5 194)
100 SC
(n 5 69)
750 IV
(n 5 29)
Age (y) (range) 50 (23-69) 49 (15-74) 49 (19-69) 46 (20-68) 50 (13-82) 51 (12-81) 49 (12-76) 50 (16-74) 50 (28-70) 48 (21-63) 50 (24-72)
Asthma duration (y),
mean 6 SD
19 6 14 20 6 14 19 6 15 18 6 14 20 6 14 21 6 13 20 6 15 17 6 12 20 6 14 20 6 16 22 6 15
On maintenance
OCS, n (%)
46 (30) 50 (33) 47 (30) 45 (29) 48 (25) 52 (27) 44 (23) 69 (100) 66 (100) 16 (57*) 17 (53)
Prebronchodilator
FEV1 (%
predicted),
mean 6 SD
60 6 16 59 6 17 61 6 16 59 6 15 61 6 18 59 6 18 62 6 18 60 6 17 58 6 19 75 6 22 72 6 20
Prebronchodilator
FEV1:FVC
ratio (%),
mean 6 SD
64 6 11 63 6 13 63 6 13 63 6 12 64 6 13 63 6 13 64 6 13 63 (12) 61 (12) 69 (11) 66 (12)
Postbronchodilator
FEV1 (%
predicted),
mean 6 SD
71 6 18 71 6 17 70 6 18 71 6 18 71 6 19 70 6 18 72 6 17 72 6 20 68 6 21 78 6 21 78 6 24
Postbronchodilator
FEV1:FVC
ratio (%),
mean 6 SD
68 6 12 66 6 13 68 6 20 67 6 12 67 6 13 66 6 13 67 6 12 67 6 13 64 6 13 72 6 10 68 6 14
Baseline blood
eosinophil count
(3109/L)
0.25 (0.95) 0.23 (1.20) 0.25 (0.93) 0.28 (1.01) 0.28 (0.99) 0.29 (1.05) 0.32 (0.94) 0.25 (1.25) 0.23 (1.00) 0.32 (0.38) 0.35 (0.30)
Exacerbations in
year before
study start§
3.7 (3.1) 3.4 (2.4) 3.5 (2.8) 3.7 (3.8) 3.5 (2.2) 3.8 (2.7) 3.6 (2.8) 3.3 (3.4) 2.9 (2.8) 5.5 5.0
Exacerbations
requiring
admission in
year before
study start, n (%)
35 (23) 36 (24) 39 (25) 40 (26) 41 (21) 33 (17) 35 (18) 14 (20) 9 (14) 8 (28)k 10 (31)k
Unless specified, values are means.
FVC, Forced vital capacity; Mepo; mepolizumab.
*N 5 28.
Geometric mean (loge SD).
Geometric mean (log10 SD).
§Rate per patient.
kBased on any admissions to the intensive care unit before the study.
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In this meta-analysis of 4 placebo-controlled studies
ranging from 24- to 52-week duration, mepolizumab treatment
resulted in an approximate halving of exacerbations requiring
hospitalization or combined hospitalization and emergency room
visit compared with placebo in patients with severe eosinophilic
asthma already receiving maximal standard of care therapy.4 This
effect was observed in the pooled analysis of all doses of
mepolizumab and in the sensitivity analysis for the 75 mg IV
and 100 mg SC doses only, showing that the 100 mg SC dose
and the comparable 75 mg IV dose achieved this same significant
effect. Similarly, the proportion of patients experiencing these
events was reduced by 45% for exacerbations requiring
hospitalization and by 38% for exacerbations requiring
hospitalization and/or emergency room visit for all doses of
mepolizumab compared with placebo. In terms of absolute
change, treatment with mepolizumab resulted in patients
experiencing an exacerbation requiring hospitalization or
hospitalization/emergency room visit every 14 and 7 years,
respectively, compared with every 7 and 3 years, respectively,with placebo and standard of care. These results suggest an
important clinical benefit for mepolizumab on a background of
appropriate standard therapy in reducing major rare events such
as hospitalizations and visits to the emergency room in severe
eosinophilic asthma. This may also have economic benefits
because patients with severe asthma place a high financial burden
on health care systems, with hospitalizations and emergency
room visits contributing a larger proportion of these costs
compared with patients with nonsevere asthma.32
Meta-analyses are important tools for assessing treatment
effects related to important, but infrequent end points. They
have increased power to detect differences compared with
individual studies and improve estimates of treatment effects.
This study has several strengths. First, all the studies included
were randomized, placebo-controlled studies. Second, the design
of the meta-analysis meant that the authors had access to
individual patient-level data. Third, there was low heterogeneity
in the outcomes between the individual studies. Fourth, only those
studies that included patients with severe eosinophilic asthma
were included. A recent Cochrane review of the efficacy of
TABLE II. Proportion of patients with more than 1 exacerbation requiring hospitalization or hospitalization/ER visit
Study
Placebo Mepolizumab (all doses, pooled) Mepolizumab (75 mg IV/100 mg SC)
N
Hospitalization
Hospitalization/
ER visit
N
Hospitalization
Hospitalization/
ER visit
N
Hospitalization
Hospitalization/
ER visit
n % n % n % n % n % n %
DREAM 155 17 11.0 27 17.4 461 37 8.0 56 12.1 153 12 7.8 15 9.8
MENSA 191 13 6.8 24 12.6 385 14 3.6 28 7.3 385 14 3.6 28 7.3
SIRIUS 66 7 10.6 7 10.6 69 0 0 3 4.3 — — — — —
Haldar et al15 32 5 15.6 — — 29 2 6.9 — — — — — — —
Combined 444 42 9.5 58 14.1* 944 53 5.6 87 9.5 538 26 4.8 43 8.0
ER, Emergency room.
*N 5 412.
N 5 915.
p=0.004
0.125 0.25 0.5 1 2 4
Favors mepo Favors placebo
p=0.004
Study
Patients with ≥1 exacerbation requiring hospitalization*
Patients with ≥1 exacerbation requiring hospitalization/ER visit†
DREAM
MENSA
Haldar 2009
Combined
DREAM
MENSA
SIRIUS
Combined
Subjects with event (%)
Placebo Mepo
11.0 8.0
6.8 3.6
15.6 6.9
9.5 5.6
17.4 12.1
12.6 7.3
10.6 4.3
14.1 9.5
0.73 (0.42, 1.26)
0.53 (0.26, 1.11)
SIRIUS 10.6 0 0
0.44 (0.09, 2.10)
0.55 (0.36, 0.83)
0.70 (0.46, 1.06)
0.58 (0.35, 0.97)
0.41 (0.11, 1.52)
0.62 (0.45, 0.86)
Relative risk
(95% CI)
Relative risk (95% CI)
A
p=0.066
0.125 0.25 0.5 1 2 4
Favors mepo Favors placebo
p=0.004
Study
DREAM
MENSA
Combined
DREAM
MENSA
Combined
Subjects with event (%)
Placebo Mepo
11.0 7.8
6.8 3.6
8.7 4.8
17.4 9.8
12.6 7.3
14.7 8.0
0.72 (0.35, 1.45)
0.53 (0.26, 1.11)
0.62 (0.38, 1.04)
0.56 (0.31, 1.02)
0.58 (0.35, 0.97)
0.57 (0.39, 0.84)
Relative risk
(95% CI)
Relative risk (95% CI)
B
Patients with ≥1 exacerbation requiring hospitalization
Patients with ≥1 exacerbation requiring hospitalization/ER visit
FIG 2. Meta-analysis of proportion of patients with 1 or more exacerbation requiring hospitalization or
hospitalization/ER visit for all doses (A) and 75 mg IV/100 mg SC (pooled) doses of mepolizumab (B) versus
placebo. Heterogeneity in hospitalization data: I25 (A) 0% (95% CI, 0-69), (B) 0% (95% CI, 0-0); heterogeneity
in hospitalization/ER visit data: I2 5 (A) 0% (95% CI, 0-72), (B) 0% (95% CI, 0-0). ER, Emergency room;Mepo,
mepolizumab. *Relative risk not calculated for SIRIUS, but data included in the meta-analysis. Data not
available for Haldar et al.15
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AB
FIG 3. Kaplan-Meier cumulative incidence curve for time to first exacerbation requiring hospitalization (A)
and hospitalization and/or ER visit (B). ER, Emergency room.
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In addition, a previous meta-analysis of the efficacy of
mepolizumab by Liu et al,14 which did not include themost recent
phase III studies, MENSA and SIRIUS, also assessed efficacy
across a wider asthma phenotype.14 Conversely, the current
analysis composed of only patients with severe eosinophilic
asthma and a history of frequent exacerbations includes the
most recent phase III study data in this patient population.14
Thus, this meta-analysis constitutes a robust analysis of
exacerbation rates requiring hospitalization and/or emergency
room visits for mepolizumab therapy in patients with severe
eosinophilic asthma.This analysis had some limitations. The analysis included
SIRIUS, which was a steroid-sparing study, and hence,
exacerbation events may have been induced by a reduction in
steroid dose, rather than being spontaneous, as they were in
MENSA, DREAM, and Haldar et al.3,15-17 However, the
sensitivity analysis, which excluded SIRIUS, showed similar
results. The maximum duration of treatment with mepolizumab
was 1 year. However, despite this short duration, the number of
patients with 1 or more exacerbation requiring hospitalization
and/or emergency room visit each year was reduced by 38% to
45%. Any reduction in exacerbations is a major benefit to
patients and health care services; exacerbations associated with
p=0.004
0.125 0.25 0.5 1 2 4
Favors mepo Favors placebo
p<0.001
Study
Exacerbations requiring hospitalization*
Exacerbations requiring hospitalization/ER visit†
DREAM
MENSA
Haldar 2009
Combined
DREAM
MENSA
SIRIUS
Combined
Subjects (n)
Placebo Mepo
155 461
191 385
32 29
378 875
155 461
191 385
66 69
412 915
0.54 (0.29, 1.00)
0.44 (0.19, 1.02)
0.27 (0.03, 2.61)
0.49 (0.30, 0.80)
0.50 (0.29, 0.85)
0.52 (0.28, 0.96)
0.35 (0.09, 1.40)
0.49 (0.33, 0.73)
Relative rate
(95% CI)
Relative rate (95% CI)
FIG 4. Meta-analysis of rate of exacerbations requiring hospitalization or hospitalization/ER visit for all
doses of mepolizumab versus placebo. Heterogeneity in hospitalization data: I25 0% (95% CI, 0-53); hetero-
geneity in hospitalization/ER visit data: I2 5 0% (95% CI, 0-22). ER, Emergency room; Mepo, mepolizumab.
*SIRIUS not included because there were no hospitalizations in the Mepo arm. Haldar et al15 not included
because data were not available for ER visits.
TABLE III. Absolute rates of hospitalization or hospitalization/ER visit per year for combined analysis
Analysis End point Studies
Mean rate per year
(no. of years before experiencing 1 exacerbation)
Placebo Mepolizumab
Meta-analysis on all
mepolizumab doses
Exacerbations requiring hospitalization*
Exacerbations requiring hospitalization
and/or ER visit
DREAM
MENSA
Haldar et al15
DREAM
MENSA
SIRIUS
0.15
(6.7)
0.31
(3.2)
0.07
(14.3)
0.15
(6.7)
Sensitivity analysis on 75 mg
IV/100 mg SC (pooled)
mepolizumab doses
Exacerbations requiring hospitalization
Exacerbations requiring hospitalization
and/or ER visit
DREAM
MENSA
DREAM
MENSA
0.14
(7.1)
0.28
(3.6)
0.07
(14.3)
0.13
(7.7)
ER, Emergency room.
*SIRIUS not included because there were no hospitalizations in the mepolizumab arm.
Haldar et al15 not included because data were not available for ER visits.
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associated with considerable morbidity and mortality as well as
a long-term risk of accelerated lung function decline.5,6,34
Furthermore, hospital admissions are expensive and contribute
disproportionately to asthma health care costs, particularly for
severe asthma.7,8 Therefore, the beneficial effect of mepolizumab
on this end point may result in significant long-term cost savings.
In this meta-analysis, approximately 36% of patients were on
daily OCS; previous studies have shown that baseline blood
eosinophil levels are similar in OCS-dependent and non–OCS-
dependent patients.27 In addition, in a subanalysis of the DREAM
study, mepolizumab was shown to have similar efficacy in
reducing exacerbation rates in these 2 groups of patients.27
Furthermore, in the SIRIUS study, where all patients were
treated with daily OCS, there were reductions in the OCS doseand the frequency of exacerbations in patients who received
mepolizumab.16 This is important because daily use of OCS is
associated with significant systemic adverse effects, which are
cumulative and dose dependent.35,36 Taken together, this suggests
that mepolizumab may have similar efficacy in reducing
exacerbations requiring hospitalization or a visit to the emergency
room in OCS-dependent and non–OCS-dependent patients with
severe eosinophilic asthma.
The importance of appropriate patient selection has been
demonstrated by the fact that mepolizumab has only minimal
efficacy in patients who were not selected by using specific
biomarkers and clinical features relevant to the target
population.12,31,37 A recent post hoc analysis of the DREAM
and MENSA studies has shown that baseline blood eosinophil
counts are biomarkers that predict increasing baseline morbidity
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measurement of blood eosinophil counts at baseline is a good
biomarker to identify patients for mepolizumab treatment. The
exacerbation rate reduction with mepolizumab versus placebo
increased progressively from 52% in patients with a baseline
eosinophil count of 150 cells/mL or more to 70% in patients
with a baseline count of 500 cells/mL or more.38 It would be
reasonable to assume that reductions in rates of hospitalizations
and hospitalization/emergency room visits stratified by baseline
eosinophil count would follow a similar pattern to exacerbation
rates; however, these events were too infrequent for meaningful
stratification in the current meta-analysis.
In summary, the results of this meta-analysis show that
mepolizumab significantly reduces the risk of exacerbations
requiring hospitalization or a visit to the emergency room. This
reduction is similar to the reductions achieved for all severe
exacerbations experienced in the pivotal trials, indicating that
mepolizumab retains therapeutic efficacy across the spectrum of
exacerbation severity. Previous studies have shown that
mepolizumab is associated with a clinically acceptable safety
profile across a number of conditions.3,15-17,31,39,40 Mepolizumab
therefore represents an important treatment option for patients
with severe eosinophilic asthma, and addresses a patient
population that currently has a high unmet need and limited
treatment options.
Editorial support (in the form of writing assistance, including the
development of the initial draft on the basis of author feedback on an initial
outline developed by the first author, collating and incorporating author
comments on all drafts, grammatical editing, and referencing) was provided
by Elizabeth Hutchinson, PhD, of Fishawack Indicia Ltd, funded by GSK.
Clinical implications:Mepolizumab represents a targeted treat-
ment option for patients with severe eosinophilic asthma, and
impacts significantly on key exacerbation-related outcomes.
This confers benefit to a population with high unmet need.REFERENCES
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FIG E1. Meta-analysis of rate of exacerbations requiring hospitalization or hospitalization/ER visit for 75 mg
IV/100mg SC (pooled) doses of mepolizumab versus placebo. Heterogeneity in hospitalization data: I25 0%
(95% CI, 0-0); heterogeneity in hospitalization/ER visit data: I2 5 0% (95% CI, 0-0). ER, Emergency room;
Mepo, mepolizumab.
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TABLE E1. Summary of studies included in the meta-analysis
Parameter DREAM (Pavord et al3) MENSA (Ortega et al17) SIRIUS (Bel et al16) Haldar et al15
Study design
Design Multicenter, randomized,
placebo-controlled,
double-blind, parallel-group
Multicenter, randomized,
placebo-controlled, double-blind,
double-dummy, parallel-group
Multicenter, randomized,
placebo-controlled, double-blind,
parallel-group
Single-center, randomized,
placebo-controlled, double-blind,
parallel-group
Drugs and regimen 75 mg IV, 250 mg IV, 750 mg
IV, or placebo every 4 wk for
52 wk (13 doses)
75 mg IV, 100 mg SC, or placebo every
4 wk for 32 wk (8 doses)
100 mg SC or placebo every 4 wk
for 24 wk (6 doses)
750 mg IV or placebo every month for
12 mo (12 doses)
Primary end point Annual rate of clinically significant
exacerbations, defined as worsening
of asthma requiring systemic
glucocorticoids for >_3 d, ER visit,
or hospitalization
Annual rate of clinically significant
exacerbations, defined as worsening of
asthma requiring systemic
glucocorticoids for >_3 d, ER visit, or
hospitalization
Percent reduction in daily oral
glucocorticoid dose during weeks
20 to 24 compared with the run-in
period
Number of severe exacerbations of
asthma per subject, defined as period
of deterioration in asthma control in
subjects who had been treated with
high-dose oral prednisolone for >_5 d
Inclusion criteria
Age group >_12 y >_12 y >_12 y >_18 y
Exacerbation history >_2 exacerbations requiring
corticosteroid treatment in
previous year
>_2 exacerbations requiring corticosteroid
treatment in previous year
Not required >_2 exacerbations requiring
corticosteroid treatment in
previous year
Sputum eosinophil count Historical or baseline 3%* Not required Not required Historical or baseline 3%
Peripheral blood eosinophil
count
Historical count (12 mo) >_300
cells/mL*
Historical count (12 mo) >_300 cells/mL
OR Baseline count >_150 cells/mL
Historical count (12 mo) >_300 cells/mL
OR Baseline count >_150 cells/mL
Not required
Baseline treatments 6 OCS High-dose ICS 1 controller 6 OCS High-dose ICS 1 controller 1 OCS >_6 mo High-dose
ICS 1 controller
6 OCS High-dose ICS 1 controller
ER, Emergency room; ICS, inhaled corticosteroid; LABA, long-acting beta2 agonist; LTRA, leukotriene receptor antagonist.
*Eosinophilic inflammation was defined by 1 of several criteria, of which sputum eosinophil and peripheral blood cell count were 2 possibilities. Patients were required to meet 1 of these criteria to be included in the study.
Controller medication: LABA, LTRA, or theophylline.
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